Exousia Pro Amends Offering Circular for Highly Dilutive Capital Raise and Shareholder Sales at Discount Amidst Going Concern Doubts

summarizeSummary

Exousia Pro, a micro-cap biotechnology company, amended its Regulation A offering circular to raise up to $905,000 for company operations and allow selling shareholders to sell up to $214,500 in shares, both at a discount to the current market price, amidst significant financial distress and going concern doubts.

check_boxKey Events

• Amended Offering Details

  The company revised its Regulation A offering to sell up to 15,000,000 common shares, aiming to raise a maximum of $905,000 for its operations.

• Selling Shareholder Offering

  Selling shareholders, including legal counsel and consultants, are offering up to 3,575,000 shares, from which the company will receive no proceeds.

• Discounted Offering Price

  Both company and selling shareholder shares are offered at $0.06 per share, a discount to the current market price of $0.0649.

• Significant Dilution

  The offering could increase outstanding common shares by over 45%, with further potential dilution from Series B Convertible Preferred Stock.

auto_awesomeAnalysis

This amended offering circular underscores Exousia Pro's critical need for capital to sustain operations, explicitly stating "doubt about our ability to continue as a viable business." The company is undertaking a highly dilutive offering, which, if fully subscribed, would increase outstanding shares by over 45%. The offering price is set at a discount to the current market price, reflecting the urgency and challenges in securing financing. A significant portion of the offering also involves selling shareholders, including the company's legal counsel and consultants, cashing out their convertible notes, from which the company receives no proceeds. This dual offering structure, combined with the company's precarious financial position and the potential for further dilution from Series B Preferred Stock, presents substantial risks for current and prospective investors. The proceeds are earmarked for essential R&D, product development, and working capital, indicating a survival strategy rather than growth.